Your browser doesn't support javascript.
loading
Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosis.
Dhindsa, Ryan S; Mattsson, Johan; Nag, Abhishek; Wang, Quanli; Wain, Louise V; Allen, Richard; Wigmore, Eleanor M; Ibanez, Kristina; Vitsios, Dimitrios; Deevi, Sri V V; Wasilewski, Sebastian; Karlsson, Maria; Lassi, Glenda; Olsson, Henric; Muthas, Daniel; Monkley, Susan; Mackay, Alex; Murray, Lynne; Young, Simon; Haefliger, Carolina; Maher, Toby M; Belvisi, Maria G; Jenkins, Gisli; Molyneaux, Philip L; Platt, Adam; Petrovski, Slavé.
Afiliación
  • Dhindsa RS; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Mattsson J; Translational Science & Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Nag A; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Wang Q; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Wain LV; Genetic Epidemiology Group, Department of Health Sciences George Davies Centre, University of Leicester, Leicester, UK.
  • Allen R; National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
  • Wigmore EM; Genetic Epidemiology Group, Department of Health Sciences George Davies Centre, University of Leicester, Leicester, UK.
  • Ibanez K; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Vitsios D; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Deevi SVV; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Wasilewski S; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Karlsson M; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Lassi G; Lung Regeneration, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Olsson H; Translational Science & Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Muthas D; Translational Science & Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Monkley S; Translational Science & Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Mackay A; Translational Science & Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Murray L; Translational Science & Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Young S; Lung Regeneration, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Haefliger C; Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Belvisi MG; Royal Brompton Hospital, London, UK.
  • Jenkins G; Hastings Centre for Pulmonary Research and Division of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
  • Molyneaux PL; National Heart and Lung Institute, Imperial College, London, UK.
  • Platt A; Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Petrovski S; Respiratory Pharmacology Group, London, UK.
Commun Biol ; 4(1): 392, 2021 03 23.
Article en En | MEDLINE | ID: mdl-33758299
Idiopathic pulmonary fibrosis (IPF) is a fatal disorder characterised by progressive, destructive lung scarring. Despite substantial progress, the genetic determinants of this disease remain incompletely defined. Using whole genome and whole exome sequencing data from 752 individuals with sporadic IPF and 119,055 UK Biobank controls, we performed a variant-level exome-wide association study (ExWAS) and gene-level collapsing analyses. Our variant-level analysis revealed a novel association between a rare missense variant in SPDL1 and IPF (NM_017785.5:g.169588475 G > A p.Arg20Gln; p = 2.4 × 10-7, odds ratio = 2.87, 95% confidence interval: 2.03-4.07). This signal was independently replicated in the FinnGen cohort, which contains 1028 cases and 196,986 controls (combined p = 2.2 × 10-20), firmly associating this variant as an IPF risk allele. SPDL1 encodes Spindly, a protein involved in mitotic checkpoint signalling during cell division that has not been previously described in fibrosis. To the best of our knowledge, these results highlight a novel mechanism underlying IPF, providing the potential for new therapeutic discoveries in a disease of great unmet need.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas de Ciclo Celular / Mutación Missense / Fibrosis Pulmonar Idiopática Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Commun Biol Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas de Ciclo Celular / Mutación Missense / Fibrosis Pulmonar Idiopática Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Commun Biol Año: 2021 Tipo del documento: Article